Cadila Healthcare has received a letter from US Food and Drug Administration (USFDA), conveying that the facilities at Moraiya are acceptable. The USFDA had earlier issued a warning letter to the company but with this it is been resolved.
Cadila Healthcare focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.
The company has posted a rise of 55.30% in its net profit at Rs 139.40 crore for the quarter ended March 31, 2012 as compared to Rs 89.76 crore for the same quarter in the previous year. Total income has increased by 13.95% at Rs 795.86 crore for quarter under review as compared Rs 698.41 crore for the quarter ended March 31, 2011.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1693.15 |
| Dr. Reddys Lab | 1221.25 |
| Cipla | 1230.75 |
| Zydus Lifesciences | 939.20 |
| Lupin | 2326.50 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: